← Patent-cliff monitor small molecule MIMRYLO RUSFERTIDE ACETATE
Loss of exclusivity March 2034 latest FDA-listed patent expiry
Company TAKEDA PHARMACEUTICALS AMERICA INC
Drug detail Brand name MIMRYLO Active ingredient RUSFERTIDE ACETATE Strength EQ 54MG BASE/VIAL Dosage form POWDER Route SUBCUTANEOUS Modality Small molecule FDA approval August 2026 Marketing status RX
Listed patents Patent Expires Type 12269856 March 2034 use U-4600 11807674 March 2034 product 10501515 March 2034 substance 10442846 March 2034 substance, product 9822157 March 2034 substance, product 10030061 March 2034 substance, product
Regulatory exclusivity Code Expires NCE August 2031
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.